![](https://img.einnews.com/small/613160/nrxp-on-the-nasdaq.jpeg)
Accelerated Approval to Treat Bipolar Depression & Akathisia Could Yield Over $150 in Revenue Per Share; (Nasdaq: NRXP)
NRx Pharmaceuticals Projects Major Revenue Boost with New Bipolar Depression and Akathisia Treatment Approval: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) $NRXP NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) WILMINGTON, DELAWARE, UNITED STATES, July 29, 2024 …